Presented at Obesity Week -
Effect of Lorcaserin on Weight Loss in Patients with Severe Obesity
Zhixiao Wang Woodcliff Lake New Jersey, Xuan Li Woodcliff Lake NJ, Annette Powers Woodcliff Lake NJ, Ken Fujioka La Jolla CA
Background: Patients (pts) with severe obesity (SO) (BMI ≥ 40 or BMI ≥ 35 with ≥1 obesity-related comorbidity) may be qualified for bariatric surgery (sur). However, some pts and payers are concerned about potential complications and high costs of sur. Effect of lorcaserin (lor) in pts with SO was assessed.
Methods: This is a post-hoc analysis of pts with SO at baseline (bl) from 3 phase 3 trials (BLOSSOM: NCT00603902, BLOOM: NCT00395135, BLOOM-DM: NCT00603291) evaluating the efficacy and safety of lor 10 mg bid vs placebo (pbo) for weight loss over 52 weeks; all pts received diet and exercise counseling. Average weight loss and percentage of patients who reduced their weight to below the SO threshold (BMI<35) were compared between patients treated with lorcaserin and those received placebo in the MITT/LOCF population with SO. Weight loss in pts with SO who lost 5% or more at week 12 (W12 responders), was also examined. Results: Average weight loss is 5.9% in pts treated with lor (average BMI at bl: 39.1), vs 2.6% in the pbo (average BMI at bl: 39.2) (P<0.001). More pts with SO at bl had BMI reduced to below 35 at wk52 with lor vs pbo (30.8% vs 16.1%, P<0.001). More pts with SO were W12 responders with lor (47.3%) compared to those with pbo (21.9%). In the W12 responders with SO, average weight loss is 10.5% in pts treated with lor, vs 9.4% in the pbo. 53.9% of W12 responder pts with lor had BMI reduced to below 35 at wk52 compared to 43.0% with pbo.
Conclusions: The effect of lor in pts with SO suggests that it may be considered for pre-sur weight loss treatment or as a potential alternative to sur in this population. However, long- term clinical and economic data are needed to further evaluate the role of lor in pts with SO.
Effect of Lorcaserin on Weight Loss in Patients with Severe Obesity
Zhixiao Wang Woodcliff Lake New Jersey, Xuan Li Woodcliff Lake NJ, Annette Powers Woodcliff Lake NJ, Ken Fujioka La Jolla CA
Background: Patients (pts) with severe obesity (SO) (BMI ≥ 40 or BMI ≥ 35 with ≥1 obesity-related comorbidity) may be qualified for bariatric surgery (sur). However, some pts and payers are concerned about potential complications and high costs of sur. Effect of lorcaserin (lor) in pts with SO was assessed.
Methods: This is a post-hoc analysis of pts with SO at baseline (bl) from 3 phase 3 trials (BLOSSOM: NCT00603902, BLOOM: NCT00395135, BLOOM-DM: NCT00603291) evaluating the efficacy and safety of lor 10 mg bid vs placebo (pbo) for weight loss over 52 weeks; all pts received diet and exercise counseling. Average weight loss and percentage of patients who reduced their weight to below the SO threshold (BMI<35) were compared between patients treated with lorcaserin and those received placebo in the MITT/LOCF population with SO. Weight loss in pts with SO who lost 5% or more at week 12 (W12 responders), was also examined. Results: Average weight loss is 5.9% in pts treated with lor (average BMI at bl: 39.1), vs 2.6% in the pbo (average BMI at bl: 39.2) (P<0.001). More pts with SO at bl had BMI reduced to below 35 at wk52 with lor vs pbo (30.8% vs 16.1%, P<0.001). More pts with SO were W12 responders with lor (47.3%) compared to those with pbo (21.9%). In the W12 responders with SO, average weight loss is 10.5% in pts treated with lor, vs 9.4% in the pbo. 53.9% of W12 responder pts with lor had BMI reduced to below 35 at wk52 compared to 43.0% with pbo.
Conclusions: The effect of lor in pts with SO suggests that it may be considered for pre-sur weight loss treatment or as a potential alternative to sur in this population. However, long- term clinical and economic data are needed to further evaluate the role of lor in pts with SO.
Effect of Lorcaserin on Weight Loss in Patients with Severe Obesity
Aucun commentaire:
Enregistrer un commentaire